Idiopathic Pulmonary Fibrosis Market Size, Share, Growth & Industry Analysis, By Drug Type (Nintedanib, Pirfenidone, Others), By Distribution Channel (Hospitals, Retail, Online), and Regional Analysis, 2024-2031

TABLE OF CONTENT

1 INTRODUCTION OF THE GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET 
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Limitations
1.5 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 Data Collection
3.1.1 Secondary Sources
3.1.2 Primary Sources
3.1.3 Research Flow
3.2 Subject Matter Expert Advice
3.3 Quality Check
3.4 Final Review
3.5 Bottom-Up Approach
3.6 Top-down Approach

4 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET OUTLOOK
4.1 Market Evolution
4.2 Overview
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.3.4 Challenges
4.4 Pricing Analysis
4.5 Porter’s Five Forces Analysis
4.6 Value Chain Analysis
4.7 Macroeconomic Analysis

5 IMPACT OF RUSSIA-UKRAINE WAR

6 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE
6.1 Overview
6.2 Nintedanib
6.3 Pirfenidone
6.4 Other 

7 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL
7.1 Overview
7.2 Hospitals
7.3 Retail
7.4 Online

8 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY END-USER
8.1 Overview
8.2 Pharmaceutical and Biopharmaceutical Companies
8.3 Contact Research Organizations
8.4 Academic and Research Institutes
8.5 Others

9 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY GEOGRAPHY
9.1 Overview

10 NORTH AMERICA 
10.1 U.S.
10.2 Canada
10.3 Mexico

11 EUROPE 
11.1 Germany
11.2 U.K.
11.3 France
11.4 Italy
11.5 Spain
11.6 Russia
11.7 Rest of Europe

12 ASIA-PACIFIC 
12.1 China
12.2 Japan
12.3 India
12.4 South Korea
12.5 Rest of Asia-Pacific

13 MIDDLE EAST & AFRICA 
13.1 GCC
13.2 South Africa
13.3 North Africa
13.4 Rest of Middle East & Africa

14 LATIN AMERICA 
14.1 Brazil
14.2 Argentina
14.3 Rest of South America

15 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET COMPETITIVE LANDSCAPE
15.1 Overview
15.2 Key Developments
15.3 Key Strategic Developments
15.4 Company Market Ranking
15.5 Regional Footprint
15.6 Industry Footprint

16 COMPANY PROFILES
16.1 Boehringer Ingelheim International GmbH
16.1.1 Key Facts
16.1.2 Financial Overview
16.1.3 Product Benchmarking
16.1.4 Recent Developments
16.1.5 Winning Imperatives
16.1.6 Current Focus & Strategies
16.1.7 Threat from competition
16.1.8 SWOT Analysis
16.2 Bristol-Myers Squibb Company
16.2.1 Key Facts
16.2.2 Financial Overview
16.2.3 Product Benchmarking
16.2.4 Recent Developments
16.2.5 Winning Imperatives
16.2.6 Current Focus & Strategies
16.2.7 Threat from competition
16.2.8 SWOT Analysis
16.3 Cipla Inc.
16.3.1 Key Facts
16.3.2 Financial Overview
16.3.3 Product Benchmarking
16.3.4 Recent Developments
16.3.5 Winning Imperatives
16.3.6 Current Focus & Strategies
16.3.7 Threat from competition
16.3.8 SWOT Analysis
16.4 Hoffmann-La Roche Ltd
16.4.1 Key Facts
16.4.2 Financial Overview
16.4.3 Product Benchmarking
16.4.4 Recent Developments
16.4.5 Winning Imperatives
16.4.6 Current Focus & Strategies
16.4.7 Threat from competition
16.4.8 SWOT Analysis
16.5  FibroGen Inc.
16.5.1 Key Facts
16.5.2 Financial Overview
16.5.3 Product Benchmarking
16.5.4 Recent Developments
16.5.5 Winning Imperatives
16.5.6 Current Focus & Strategies
16.5.7 Threat from competition
16.5.8 SWOT Analysis
16.6 MediciNova Inc.
16.6.1 Key Facts
16.6.2 Financial Overview
16.6.3 Product Benchmarking
16.6.4 Recent Developments
16.6.5 Winning Imperatives
16.6.6 Current Focus & Strategies
16.6.7 Threat from competition
16.6.8 SWOT Analysis
16.7 Merck & Co. Inc.
16.7.1 Key Facts
16.7.2 Financial Overview
16.7.3 Product Benchmarking
16.7.4 Recent Developments
16.7.5 Winning Imperatives
16.7.6 Current Focus & Strategies
16.7.7 Threat from competition
16.7.8 SWOT Analysis
16.8 Avalyn Pharma Inc.
16.8.1 Key Facts
16.8.2 Financial Overview
16.8.3 Product Benchmarking
16.8.4 Recent Developments
16.8.5 Winning Imperatives
16.8.6 Current Focus & Strategies
16.8.7 Threat from competition
16.8.8 SWOT Analysis
16.9 CS Pharmaceuticals
16.9.1 Key Facts
16.9.2 Financial Overview
16.9.3 Product Benchmarking
16.9.4 Recent Developments
16.9.5 Winning Imperatives
16.9.6 Current Focus & Strategies
16.9.7 Threat from competition
16.9.8 SWOT Analysis
16.10 Novartis AG 
16.10.1 Key Facts
16.10.2 Financial Overview
16.10.3 Product Benchmarking
16.10.4 Recent Developments
16.10.5 Winning Imperatives
16.10.6 Current Focus & Strategies
16.10.7 Threat from competition
16.10.8 SWOT Analysis

LIST OF TABLES

TABLE 1 Global Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 2 Global Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 3 Global Idiopathic Pulmonary Fibrosis Market Revenue, By Geography, 2021 – 2031 (USD Million)
TABLE 4 North America Idiopathic Pulmonary Fibrosis Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 5 North America Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 6 North America Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 7 US Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 8 US Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 9 Canada Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 10 Canada Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 11 Mexico Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 12 Mexico Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 13 Europe Idiopathic Pulmonary Fibrosis Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 14 Europe Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 15 Europe Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 16 Germany Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 17 Germany Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 18 France Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 19 France Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 20 U.K. Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 21 U.K. Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 22 Spain Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 23 Spain Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 24 Italy Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 25 Italy Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 26 Russia Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 27 Russia Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 28 Rest of Europe Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 29 Rest of Europe Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 30 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 31 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 32 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 33 China Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 34 China Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 35 Japan Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 36 Japan Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 37 India Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 38 India Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 39 South Korea Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 40 South Korea Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 41 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 42 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 43 Middle East and Africa Idiopathic Pulmonary Fibrosis Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 44 Middle East and Africa Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 45 Middle East and Africa Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 46 GCC Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 47 GCC Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 48 North Africa Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 49 North Africa Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 50 South Africa Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 51 South Africa Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 52 Rest of Middle East & Africa Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 53 Rest of Middle East & Africa Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 54 Latin America Idiopathic Pulmonary Fibrosis Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 55 Latin America Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 56 Latin America Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 57 Brazil Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 58 Brazil Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 59 Argentina Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 60 Argentina Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 61 Rest of Latin America Idiopathic Pulmonary Fibrosis Market Revenue, By Drug Type, 2021 – 2031 (USD Million)
TABLE 62 Rest of Latin America Idiopathic Pulmonary Fibrosis Market Revenue, By Distribution Channel, 2021 – 2031 (USD Million)
TABLE 63 Company Market Ranking
TABLE 64 Regional Footprint
TABLE 65 Product Benchmarking
TABLE 66 Recent Developments
TABLE 67 Winning Imperatives 

LIST OF FIGURES

FIG. 1 Market Segmentation
FIG. 2 Research Timeline
FIG. 3 Global Idiopathic Pulmonary Fibrosis Market 2021-2031 (USD Million)
FIG. 4 Global Idiopathic Pulmonary Fibrosis Market Geographical Analysis (CAGR %)
FIG. 5 Global Idiopathic Pulmonary Fibrosis Absolute Market Opportunity (USD Million)
FIG. 6 Global Idiopathic Pulmonary Fibrosis Market Attractiveness (USD Million)
FIG. 7 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type, 2021-2031 (USD Million)
FIG. 8 Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2021-2031 (USD Million)
FIG. 9 Research Methodology
FIG. 10 Research Process
FIG. 11 Bottom-Up Approach
FIG. 12 Top-Bottom Approach
FIG. 13 Market Dynamics Overview
FIG. 14 Porter's Five Forces Analysis
FIG. 15 Value Chain Analysis
FIG. 16 Macroeconomic Analysis
FIG. 17 Global Idiopathic Pulmonary Fibrosis Market Revenue Share, By Drug Type, 2023 and 2031 (%)
FIG. 18 Global Idiopathic Pulmonary Fibrosis Market Revenue Share, By Distribution Channel, 2023 and 2031 (%)
FIG. 19 Global Idiopathic Pulmonary Fibrosis Market Revenue Share, By Geographic Regions, 2023 and 2031 (%)
FIG. 20 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 21 North America Idiopathic Pulmonary Fibrosis Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 22 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 23 Europe Idiopathic Pulmonary Fibrosis Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 24 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 25 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 26 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 27 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 28 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 29 Latin America Idiopathic Pulmonary Fibrosis Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 30 Key Strategic Development
FIG. 31 Key Facts
FIG. 32 Financial Overview
FIG. 33 SWOT Analysis